Clinical Research of Rebamipide-based Quadruple Therapy for Helicobacter Pylori Eradication

Yan Wenjuan

Abstract：Objective To observe and compare the efficacy and cost-effective of rebamipide-based quadruple therapy versus bismuth-based quadruple therapy. Methods 124 patients were randomly assigned to treatment group and control group. Lansoprazole 30 mg,amoxicillin 1000 mg,furazolidone 100 mg twice a day and rebamipide 100 mg three times a day were administrated to 65 patients in treatment group. Lansoprazole 30 mg,amoxicillin 1000 mg,fura-zolidone 100 mg and Bismuth 220 mg twice a day were administrated to 59 patients in control group. Courses of treat-ment were both 10 days. Hp eradication was estimated by 14C urea breath test at the 38th day after treatment. Cost-effectiveness was analyzed;adverse effects were recorded and analyzed. Data were analyzed by chi square test. Results The eradication rates of treatment group and control group were 72. 3%(47/65)and 81. 4%(48/59)respectively. There was no significant difference(P﹥0. 05)between these two groups. The cost in treatment group and control group were 164. 95 and 250. 1 yuan. Cost-effectiveness in treatment group was significantly better than that in control group (P﹤0. 05). Rates of side effects in treatment group and control group were 12. 31%(8/65)and 15. 26%(9/59)re-spectively. There was no significant difference between the two groups(P﹥0. 05). No serious adverse effect was ob-served in two groups. Conclusion Effectiveness and safety are almost the same between the two groups. However,Re-bamipide-based quadruple therapy has better cost-effectiveness,which is suitable for clinical application.